Explore the Agenda
8:20 am Registration & Networking
8:55 am Chair’s Opening Remarks
Latest Clinical & R&D Advances in Gastrointestinal Indications Disorders Driving Therapeutic Innovation
9:00 am Ultra-Purified Microbial Fractions: A New Frontier in FMT-Derived Therapeutics
- Showcase a proprietary manufacturing process that isolates microbial fractions while discarding faecal material
- Present preclinical data in infectious disease, melanoma, and colorectal cancer models
- Prepare for IND submission and clinical trial initiation to validate cross-indication potential
9:30 am Re-evaluating FMT as a Bridge Between Academic Insight & Therapeutic Innovation in IBD
- Introducing trials exploring FMT in ulcerative colitis and PSC to investigate disease modification and mechanistic insight
- Address disconnects between academic research and industry sentiment around FMT and LBPs, and propose frameworks to realign innovation
- Position FMT as both a therapeutic and diagnostic tool to inform future live biotherapeutic development
10:00 am Morning Break & Poster Session
Enhancing Translational Accuracy Through Advanced Preclinical Models
11:00 am Update on BEO 001 Clinical Proof-of-Concept Study
- Ongoing clinical trial in 99 patients to evaluate BEO 001 efficacy and safety
- Predictive response model predicting clinical efficacy
11:30 am Reprogramming the Microbiome: Engineering Phage-Resistant LBPs for Durable Therapeutic Impact
- Demonstrate how CRISPR-enhanced bacterial strains resist phage attack to improve engraftment and therapeutic persistence
- Leverage virome analysis to uncover viral drivers of LBP failure across women’s health and gut indications
- Expand platform applications from vaginal microbiome to gut disorders, showcasing data from preclinical developments
12:00 pm Lunch Break & Networking
Exploring Novel Modalities & Combination Strategies to Expand Therapeutic Potential
1:30 pm Exploring Microbiome–Drug Synergies to Strengthen Mechanistic Evidence & Therapeutic Impact
- Present pilot data on combining Anaerobutyricum soehngenii with metformin to enhance glycemic control and reduce blood pressure in type 2 diabetes
- Evaluate how microbial therapies can mitigate drug-induced microbiota disruption and amplify host metabolic responses
- Discuss future directions for combination strategies, including prebiotics and multistrain consortia, and how spatial insights could support mechanistic understanding
2:00 pm Mapping the Microbial World Through Massive Phenotypic Screens & Artificial Intelligence
- Enabled by our MIT-developed combinatorial screening platform kChip, Concerto Biosciences’ ecological map of the microbial world incorporates 40+ million experimental measurements of microbial community behavior. This data trains our proprietary AI, kAI, to expand the map further still
- From this unique vantage, hundreds of robust, synergistic, and multifunctional microbe-based ingredient hits stand out in plain view. The first was ENS-002, a three-strain biotherapeutic that successfully completed Phase 1 clinical testing for atopic dermatitis
- We are now unleashing the full might of our platform and data in consumer health, beginning with deodorant and moving toward other applications in skin health and beyond
2:30 pm Harnessing Microbial Therapeutics to Prime Immunity & Expand Cancer Treatment Possibilities
- Explore IO Prime as a strategy to enhance immune readiness and improve response to existing therapies
- Demonstrate how trained immunity and microbial reprogramming can unlock new combination approaches in oncology
- Understand the rationale behind an upcoming trial using attenuated oral salmonella
3:00 pm Afternoon Break & Refreshments
Understanding the Global Regulatory Landscape & Accessibility Challenges for Microbiome Therapeutics & Consumer Health Products
3:30 pm Harnessing Microbial Insights for Innovative Consumer Product Development
- Explore the complex interactions within the human microbiome and how these dynamics influence health and product efficacy in multiple areas including skin and oral care
- Discuss the integration of multiomics technologies, such as RNASeq and metagenomics, proteomics to uncover the mechanisms of microbial response to therapeutic ingredients
- Illustrate case studies from Procter & Gamble that demonstrate how microbiome research translates into actionable strategies for consumer product development, emphasising the role of biomarkers and mechanistic understanding in driving innovation